Induction of Plasminogen Activator Inhibitor Type-1 (PAI-1) by Proinsulin and Insulin In Vivo
- 1 February 1995
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 91 (3), 764-770
- https://doi.org/10.1161/01.cir.91.3.764
Abstract
Background Fasting hyperinsulinemia (reflected by elevations in immunoreactive “insulin”) is typical of patients with non–insulin-dependent diabetes mellitus (NIDDM) and is often associated with obesity and hypertension. The elevated concentrations detected are indicative not only of insulin but also of its immunologically cross-reactive precursors, including proinsulin. Fasting hyperinsulinemia appears to be associated with decreased fibrinolytic activity in blood, which results from increased activity of plasminogen activator inhibitor type-1 (PAI-1), a potential independent risk factor for coronary artery disease. Patients who were given proinsulin in a previous clinical study by others exhibited an increased incidence of cardiovascular events. Thus, a “proinsulin–PAI-1 axis” may predispose to coronary thrombosis. To define the possible presence of such an axis, this study was designed to determine whether insulin, its precursors, or both increase the concentrations of PAI-1 in rabbits in vivo. Methods...Keywords
This publication has 36 references indexed in Scilit:
- Insulin Therapy in Type 2 Diabetic Subjects Suppresses Plasminogen Activator Inhibitor (PAI‐1) Activity and Proinsulin‐like Molecules Independently of Glycaemic ControlDiabetic Medicine, 1993
- Substrate-bound fibrinogen, fibrin and other cell attachment-promoting proteins as a scaffold for cultured vascular smooth muscle cellsAtherosclerosis, 1992
- Biosynthetic Human Proinsulin: Review of Chemistry, in Vitro and in Vivo Receptor Binding, Animal and Human Pharmacology Studies, and Clinical Trial ExperienceDiabetes Care, 1992
- Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarctionThe American Journal of Cardiology, 1989
- Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1989
- Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and strokeThe American Journal of Cardiology, 1988
- Bioactivity and Pharmakokinetics of Human Proinsulin in Comparison to Human Insulin after Intravenous and Subcutaneous InjectionHormone and Metabolic Research, 1988
- PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTIONThe Lancet, 1987
- The Effects of Biosynthetic Human Proinsulin on Carbohydrate Metabolism in Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1987
- The sulphite precipitation method for fibrinogen measurement; Its use on small samples in the presence of fibrinogen degradation productsClinica Chimica Acta; International Journal of Clinical Chemistry, 1976